Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

391 articles

Keyword: Cancer therapyClear keyword
Nature Reviews Immunology2019ReviewNon-viral Gene Delivery

1. DNA-Stimulated Cell Death: Implications for Host Defence, Inflammatory Diseases and Cancer

Søren R. Paludan, Line S. Reinert, Veit Hornung

DNA in abnormal cellular compartments (cytosol, endosomes, micronuclei) is a potent danger signal for the innate immune system, primarily known for inducing type I interferons and IL-1β. More recently, it has become clear that cytosolic DNA also triggers various forms of programmed cell death (PCD), but the pathways and biological implications of DNA-stimulated cell death remain incompletely understood. This review addresses the gap in understanding how DNA-sensing pathways engage PCD and how these processes shape host defence, inflammatory diseases, and cancer. --- - AIM2-mediated cell death: Cytosolic DNA triggers AIM2-ASC-dependent pyroptosis via caspase-1 and gasdermin D; in the absence of caspase-1 or with low DNA, ASC recruits caspase-8 to induce apoptosis. - STING-mediated apoptosis: STING can induce apoptosis via an IRF3-BAX complex (RIPA pathway) independent of IRF3 transcriptional activity but requiring TBK1; this pathway oper

Read the article
Advanced Drug Delivery Reviews2015ReviewNon-viral Gene Delivery

2. In Vivo Delivery of miRNAs for Cancer Therapy: Challenges and Strategies

Yunching Chen, Dong-Yu Gao, Leaf Huang

miRNAs can simultaneously regulate multiple cancer-related genes, making them attractive therapeutic agents or targets. However, efficient, specific, and safe systemic delivery of therapeutic miRNAs in vivo remains a major challenge due to rapid degradation, poor tumor penetration, immunotoxicity, endosomal trapping, off-target effects, and saturation of miRNA-processing enzymes. This review discusses these barriers and current strategies to deliver miRNAs for cancer therapy without inducing toxicity. --- - Local let-7 delivery: intranasal lentiviral let-7a inhibited K-ras-dependent lung tumors; local synthetic let-7b reduced tumor size by 60–70% after four treatments at 3-day intervals. - Modified miR-143: systemic administration of passenger-strand-modified miR-143 produced 15% (low dose) to 50% (high dose) tumor growth inhibition in xenografted DLD-1 human colorectal tumors. - Neutral lipid delivery: systemic miR-34a or let-7 mimics

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.

Articles | Brilliant Blue Biosciences